Does the media refer more to AMRX or VIR?

In the previous week, Amneal Pharmaceuticals had 15 more articles in the media than Vir Biotechnology. MarketBeat recorded 21 mentions for Amneal Pharmaceuticals and 6 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.39 beat Amneal Pharmaceuticals' score of 0.88 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VIR or SRRK?

In the previous week, Scholar Rock had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 8 mentions for Scholar Rock and 6 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.39 beat Scholar Rock's score of 0.98 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VIR or DNTH?

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 6 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.39 beat Dianthus Therapeutics' score of 1.39 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VIR or TWST?

In the previous week, Twist Bioscience had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 8 mentions for Twist Bioscience and 6 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.39 beat Twist Bioscience's score of 1.24 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor VIR or ORKA?

In the previous week, Vir Biotechnology had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 6 mentions for Vir Biotechnology and 4 mentions for Oruka Therapeutics. Vir Biotechnology's average media sentiment score of 1.39 beat Oruka Therapeutics' score of 1.25 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vir Biotechnology (VIR) Competitors

$8.66 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$8.67 +0.01 (+0.08%)

As of 07/31/2026 07:34 PM Eastern

Compare

VIR vs. AMRX, SRRK, DNTH, TWST, and ORKA

Should you buy Vir Biotechnology stock or one of its competitors? MarketBeat compares Vir Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vir Biotechnology include Amneal Pharmaceuticals (AMRX), Scholar Rock (SRRK), Dianthus Therapeutics (DNTH), Twist Bioscience (TWST), and Oruka Therapeutics (ORKA).

How does Vir Biotechnology compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Amneal Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.94	$72.06M	$0.49	37.39
Vir Biotechnology	$64.69M	22.58	-$437.99M	-$3.13	N/A

Amneal Pharmaceuticals has a net margin of 5.05% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Amneal Pharmaceuticals had 15 more articles in the media than Vir Biotechnology. MarketBeat recorded 21 mentions for Amneal Pharmaceuticals and 6 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.39 beat Amneal Pharmaceuticals' score of 0.88 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	9 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals currently has a consensus target price of $17.33, suggesting a potential downside of 5.39%. Vir Biotechnology has a consensus target price of $20.88, suggesting a potential upside of 141.05%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Amneal Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

Summary

Amneal Pharmaceuticals and Vir Biotechnology tied by winning 8 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Scholar Rock?

Vir Biotechnology (NASDAQ:VIR) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, Scholar Rock had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 8 mentions for Scholar Rock and 6 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.39 beat Scholar Rock's score of 0.98 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vir Biotechnology currently has a consensus price target of $20.88, suggesting a potential upside of 141.05%. Scholar Rock has a consensus price target of $56.21, suggesting a potential upside of 18.87%. Given Vir Biotechnology's higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Scholar Rock has lower revenue, but higher earnings than Vir Biotechnology. Scholar Rock is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$64.69M	22.58	-$437.99M	-$3.13	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Vir Biotechnology has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Scholar Rock has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Scholar Rock	N/A	-163.52%	-96.67%

Summary

Vir Biotechnology and Scholar Rock tied by winning 8 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Dianthus Therapeutics?

Vir Biotechnology (NASDAQ:VIR) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Vir Biotechnology presently has a consensus target price of $20.88, indicating a potential upside of 141.05%. Dianthus Therapeutics has a consensus target price of $117.82, indicating a potential upside of 10.19%. Given Vir Biotechnology's higher probable upside, equities research analysts plainly believe Vir Biotechnology is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 6 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.39 beat Dianthus Therapeutics' score of 1.39 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vir Biotechnology has a net margin of -638.88% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Dianthus Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$64.69M	22.58	-$437.99M	-$3.13	N/A
Dianthus Therapeutics	$1.34M	4,374.92	-$162.34M	-$4.13	N/A

Vir Biotechnology has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Summary

Vir Biotechnology and Dianthus Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Twist Bioscience?

Vir Biotechnology (NASDAQ:VIR) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Vir Biotechnology presently has a consensus target price of $20.88, indicating a potential upside of 141.05%. Twist Bioscience has a consensus target price of $90.30, indicating a potential downside of 1.37%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Vir Biotechnology has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market.

Twist Bioscience has higher revenue and earnings than Vir Biotechnology. Twist Bioscience is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$64.69M	22.58	-$437.99M	-$3.13	N/A
Twist Bioscience	$409.48M	13.92	-$77.67M	-$1.33	N/A

65.3% of Vir Biotechnology shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 3.1% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Twist Bioscience had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 8 mentions for Twist Bioscience and 6 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.39 beat Twist Bioscience's score of 1.24 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Twist Bioscience has a net margin of -19.85% compared to Vir Biotechnology's net margin of -638.88%. Twist Bioscience's return on equity of -26.73% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Summary

Twist Bioscience beats Vir Biotechnology on 10 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Oruka Therapeutics?

Vir Biotechnology (NASDAQ:VIR) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Vir Biotechnology has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vir Biotechnology had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 6 mentions for Vir Biotechnology and 4 mentions for Oruka Therapeutics. Vir Biotechnology's average media sentiment score of 1.39 beat Oruka Therapeutics' score of 1.25 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Oruka Therapeutics' return on equity of -26.16% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Oruka Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$64.69M	22.58	-$437.99M	-$3.13	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Vir Biotechnology currently has a consensus price target of $20.88, suggesting a potential upside of 141.05%. Oruka Therapeutics has a consensus price target of $134.30, suggesting a potential upside of 39.16%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe Vir Biotechnology is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Vir Biotechnology beats Oruka Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Vir Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIR vs. The Competition

Export

Metric	Vir Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.46B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-2.77	7.38	282.30	24.66
Price / Sales	22.58	1,200.34	563.12	75.93
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.57	16.96	10.96	6.07
Net Income	-$437.99M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-1.59%	-1.77%	-0.64%	-0.44%
1 Month Performance	-13.75%	-8.39%	-5.23%	-4.81%
1 Year Performance	72.17%	48.40%	61.97%	18.61%

Vir Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIR Vir Biotechnology	2.9364 of 5 stars	$8.66 flat	$20.88 +141.1%	+72.2%	$1.46B	$64.69M	N/A	580	Positive News Upcoming Earnings Gap Up
AMRX Amneal Pharmaceuticals	2.8875 of 5 stars	$18.09 +0.9%	$16.60 -8.2%	+134.0%	$5.72B	$3.02B	47.61	8,500	Trending News Analyst Forecast
SRRK Scholar Rock	3.1437 of 5 stars	$48.93 +2.6%	$56.00 +14.4%	+30.1%	$5.71B	N/A	N/A	140	Upcoming Earnings Gap Up
DNTH Dianthus Therapeutics	2.1214 of 5 stars	$104.49 +0.6%	$117.82 +12.8%	+419.3%	$5.68B	$2.04M	N/A	80	Positive News Upcoming Earnings Gap Up
TWST Twist Bioscience	1.427 of 5 stars	$86.54 -4.1%	$90.30 +4.3%	+171.8%	$5.62B	$409.48M	N/A	990	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIR) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Competitors

VIR vs. AMRX, SRRK, DNTH, TWST, and ORKA

How does Vir Biotechnology compare to Amneal Pharmaceuticals?

Summary

How does Vir Biotechnology compare to Scholar Rock?

Summary

How does Vir Biotechnology compare to Dianthus Therapeutics?

Summary

How does Vir Biotechnology compare to Twist Bioscience?

Summary

How does Vir Biotechnology compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Competitors

VIR vs. AMRX, SRRK, DNTH, TWST, and ORKA

How does Vir Biotechnology compare to Amneal Pharmaceuticals?

Which has better earnings and valuation, AMRX or VIR?

Is AMRX or VIR more profitable?

Does the media refer more to AMRX or VIR?

Do analysts prefer AMRX or VIR?

Do institutionals and insiders have more ownership in AMRX or VIR?

Which has more volatility and risk, AMRX or VIR?

Summary

How does Vir Biotechnology compare to Scholar Rock?

Does the media prefer VIR or SRRK?

Do analysts prefer VIR or SRRK?

Which has better valuation & earnings, VIR or SRRK?

Which has more volatility and risk, VIR or SRRK?

Do insiders and institutionals have more ownership in VIR or SRRK?

Is VIR or SRRK more profitable?

Summary

How does Vir Biotechnology compare to Dianthus Therapeutics?

Do insiders & institutionals believe in VIR or DNTH?

Do analysts recommend VIR or DNTH?

Does the media favor VIR or DNTH?

Is VIR or DNTH more profitable?

Which has preferable valuation and earnings, VIR or DNTH?

Which has more volatility and risk, VIR or DNTH?

Summary

How does Vir Biotechnology compare to Twist Bioscience?

Do analysts recommend VIR or TWST?

Which has more risk & volatility, VIR or TWST?

Which has preferable valuation and earnings, VIR or TWST?

Do insiders and institutionals believe in VIR or TWST?

Does the media prefer VIR or TWST?

Is VIR or TWST more profitable?

Summary

How does Vir Biotechnology compare to Oruka Therapeutics?

Which has more risk & volatility, VIR or ORKA?

Do insiders & institutionals have more ownership in VIR or ORKA?

Does the media favor VIR or ORKA?

Is VIR or ORKA more profitable?

Which has better earnings and valuation, VIR or ORKA?

Do analysts rate VIR or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools